The Unraveling of Gildan's "Healthy" Inventory Claims
There's no sugarcoating it: shareholders of Gildan Activewear (NYSE: GIL) took a gut-punch today as the company's stock tanked nearly 19%. The cause? Allegations by short-seller Jehoshaphat Research suggesting a bloated $510 million in excess inventory stuffed into distributor channels, a stark contradiction to Gildan's "healthy" inventory praises.
Discrepancies That Can't Be Ignored
The word from the top brass at Gildan has been consistent—inventory levels were just peachy. CEO Glenn Chamandy told shareholders back in April 2025, "inventory's in good balance." A few months later, he boasted about sustained momentum in the distributor channel. Fast forward to Q1 2026, and they reported nearly $1.2 billion in "record" net sales.
"As far as the inventory in the channel, it's in good balance." — Glenn Chamandy, Q1 2025 Earnings Call
Yet here we are, with significant doubts cast on those rosy declarations. It's a classic case of he-said-she-said, and until all the facts spill out, investors are left holding the bag. No wonder folks are turning towards Levi & Korsinsky to sort through this mess.
Legal Recourse: Levi & Korsinsky Steps In
With such a sharp drop following the allegations, it's no surprise investors are scrambling to recover their losses. Enter Levi & Korsinsky, LLP—a firm with a reputation for going to bat for shareholders who've been wronged. They're diving into Gildan's records with a magnifying glass, looking for any false or misleading disclosures regarding those inventory numbers.
- Shareholders are encouraged to provide purchase records and losses.
- Investigation explores misleading statements on inventory health.
- No cost to participate—handled on a contingency basis.
- Open to international investors who traded U.S. exchange stocks.
Investors' Next Moves
For those who've already sold their Gildan shares at a loss, take heart—you might still be in the game for recovery. It's about when you bought, not when you sold. Step one? Gather your brokerage statements to document your trades. Levi & Korsinsky stands by with no-obligation evaluations for investors. Whether you're still in or out of Gildan, it might be worth a little of your time.
The Fallout Across the Market
The stock slide is no small fried pickle in the world of equities. It serves as a chilling reminder about the importance of transparency and trust in executive communications. The market won't take kindly to allegations—founded or not—of deception from a company's leadership.
If this situation reminds us of anything, it’s that the market can turn on a dime, and confidence, once shaken, isn't easily restored. Watching leviathan shareholders and institutions react this week will be telling as they decide whether to keep the faith or jump ship.
Stay tuned, folks, because as investigations unfold, this story is bound to morph and shift more than a soap opera plot twist. Keep one eye on the ticker (NYSE: GIL) and the other on legal updates—it’s gonna be an interesting ride.
